MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 182 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

    The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

  • Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

    VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

  • Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

    A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MV7DfZRwfG:6aXOgRZN{[Xl? MnHJN{DPxE1? M3nSSVczKGh? M{K1N2ROW09? NWj4cphVUW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= MmSzNlA2PzFyNkm=
A431 NX;XbW1xU2mwYYPlJGF{e2G7 MmrKOUDPxE1? M{G5[|UhcA>? M3nGb2ROW09? Ml:4V5VxeHKnc4Pld{B1cGVic3nncoFtcW6pIH;mJGFsfCCjbnSgSZJs NUXvT2pYOjB3N{GwOlk>
HepG2 MnPvR5l1d3SxeHnjJGF{e2G7 NYDmZXl[OTBizszN M1PYUFI1KGh? M{PpVmROW09? MYTT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NVft[Hp2OjF{MEW5NlU>
Sk-Hep1 NVqyXnJrS3m2b4TvfIlkKEG|c3H5 NXHaNGU{OTBizszN MWqyOEBp Mk[0SG1UVw>? NVLkbVlkW2Wwc3n0bZpmeyC{ZYPpd5RidnRiY3XscJMhfG9idHjlJIN6fG:2b4jpZ{Bm\m[nY4Sgc4Yhe2:{YX\lcolj MlzCNlEzODV7MkW=
OCUT1 cells harbored PIK3CA (H1047R+/+) M2TVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmzXnI{KM7:TR?= Ml3GOUBl NHvNV45FVVOR NY\oXo1sUUN3ME2wMlE1KM7:TR?= MXuyNVI5QTJ4Nx?=
K1 cells harbored PIK3CA (E542K+/+) NH\1Wm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\XN{DPxE1? MWG1JIQ> Mme4SG1UVw>? M1WydmlEPTB;MD61NkDPxE1? MXyyNVI5QTJ4Nx?=
FTC133 cells harbored PTEN (allele deletion and R130+) NFf0dVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSzJO69VQ>? NFTydGI2KGR? NHjsbmVFVVOR NUDNXoR[UUN3ME2wMlE5KM7:TR?= NVfxW3V3OjF{OEmyOlc>
C643 cells harbored HRAS (G13R+/−) NYfpRohHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L4PFMh|ryP Mmf4OUBl NVq5TohVTE2VTx?= M2mzfWlEPTB;MD6yO{DPxE1? M1TZRVIyOjh7Mk[3
Hth7 cells harbored NRAS (Q61R+/−) M1rqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXjN{DPxE1? MmnmOUBl MUPEUXNQ NGniVIVKSzVyPUSuOUDPxE1? MYiyNVI5QTJ4Nx?=
TPC1 cells harbored RET/PTC1 rearrangement MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj3N{DPxE1? MmfHOUBl MlPkSG1UVw>? M1jvbGlEPTB;MD61PUDPxE1? MljYNlEzQDl{Nke=
Hth74 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S1V|Mh|ryP Ml3COUBl NW\3Uo5WTE2VTx?= MoK3TWM2OD1{LkG5JO69VQ>? M3y3dlIyOjh7Mk[3
KAT18 NH[yZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M334cVMh|ryP NV;3THdPPSCm MYjEUXNQ NVi1NpY3UUN3ME20MlYzKM7:TR?= NX[5e4d6OjF{OEmyOlc>
SW1736 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\zSFExOCEQvF2= M2rONlUh\A>? M2nnZWROW09? NW[xOJl1UUN3ME20O{42PiEQvF2= NHzsV3IzOTJ6OUK2Oy=>
WRO MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGxNFAxKM7:TR?= Mn;2OUBl NX75[lRmTE2VTx?= M2LGNGlEPTB-MUCwNEDPxE1? NYK3NmNEOjF{OEmyOlc>
TAD2 NEGybW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6yNVAxOCEQvF2= M{niVFUh\A>? MW\EUXNQ NYDNe28{UUN3ME6xNFAxKM7:TR?= NIqzToozOTJ6OUK2Oy=>
LN229 NYeybphNSXCxcITvd4l{KEG|c3H5 MXKwMlUh|ryP MWS2NEBp NVS1PI5LTE2VTx?= NETaOYNCfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= NYHFR2x2OjJyNUe5NVQ>
T98G MYTBdI9xfG:|aYOgRZN{[Xl? Ml\SNE42KM7:TR?= MljDOlAhcA>? MUTEUXNQ NE\MdJRCfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= MVeyNlA2PzlzNB?=
HC11 M{Plb2Z2dmO2aX;uJGF{e2G7 Ml;CNVAh|ryP M1TYTVI1KGh? MnWwSG1UVw>? NWnSbG9XUW6qaXLpeJMh|rJvY3Hz[YlvKGGwZDDBSHJRKHO7boTo[ZNqew>? NYfWWlhTOjJ2Mk[2NlE>
MOLT-4 MoPCR5l1d3SxeHnjJGF{e2G7 MoO0NVAh|ryP NUnnZo8xPDhiaB?= MoW3SG1UVw>? NWPHflk{UUN3ME2xMlfjiIoQvF2= M4D6c|IzPjF2MkSz
CEM-R M1\IcWN6fG:2b4jpZ{BCe3OjeR?= MlHBNVAh|ryP NHrlTYw1QCCq MVzEUXNQ M3rtW2lEPTB;Mz6z5qCK|ryP Mmq5NlI3OTR{NEO=
CEM-S NHW0dHpEgXSxdH;4bYMhSXO|YYm= NVToeWg{OTBizszN MXi0PEBp M4KyRWROW09? NH[wRYNKSzVyPUWuNgKBkc7:TR?= M3HsOlIzPjF2MkSz
MOLT-4 MoPsSpVv[3Srb36gRZN{[Xl? NHz5[FEyOCEQvF2= MVqyOEBp M2nzRmROW09? MoH3Roxw[2u|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? MmLXNlI3OTR{NEO=
MOLT-4 MX3GeY5kfGmxbjDBd5NigQ>? MUS05qCK|ryP NIXHb5E1KGh? NXuyUlNDTE2VTx?= MWXJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFM1GvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> MV2yNlYyPDJ2Mx?=
CEM-R M3TPXGZ2dmO2aX;uJGF{e2G7 NVjDTW9EPOLCid88US=> MVW0JIg> NGm3VJFFVVOR MV3JcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNFGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> NFrqZoEzOjZzNEK0Ny=>
CEM-S M3nte2Z2dmO2aX;uJGF{e2G7 NYDNSGJQPOLCid88US=> MYC0JIg> NWe0UY5HTE2VTx?= MUnJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNVGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> NETwUHAzOjZzNEK0Ny=>
HepG2 cell MV;LbY5ie2ViQYPzZZk> MnfJNlAh|ryP M1P0WlI1KGh? M{XO[WROW09? NFPmTG9Fd3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW MnX2NlM4QTd|MUm=
HepG2 cell NGfhOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrwN|Ah|ryP MV2yOEBp NH7wRXpFVVOR MVPJcohq[mm2czDj[YxtKGe{b4f0bC=> NX74ZZNKOjN5OUezNVk>
HepG2 cell M3G1eGFxd3C2b4Ppd{BCe3OjeR?= MXWyNEDPxE1? MmjKNlQhcA>? MmX2SG1UVw>? NWDIU5JRUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MnnONlM4QTd|MUm=
GEO M1Pjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzCOVAxKG6P MnrBO|IhcA>? NV;ER29XTE2VTx?= MYrJcohq[mm2czDj[YxtKGe{b4f0bC=> Mn\0NlQ2QDF{M{G=
CNE-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfaV3ZDOTBizszN NHrVVYU6PiCq MXvEUXNQ M{HtcmlEPTB;Mj65OkDPxE1? NEjW[IszPTN|NkmyOS=>
CNE-2 M165fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPBNVAh|ryP MlTEPVYhcA>? NG\LVZFFVVOR MoPzTWM2OD12LkWzJO69VQ>? NFvZb|QzPTN|NkmyOS=>
HONE-1 NW\lOZN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvYNVAh|ryP NV\1ZXNHQTZiaB?= NV;0WI9WTE2VTx?= NWjMPG5[UUN3ME2zMlM4KM7:TR?= NHfsVoMzPTN|NkmyOS=>
SUNE-1 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fSRlExKM7:TR?= MojKPVYhcA>? NG\hXGRFVVOR NVvienBPUUN3ME2wMlUzKM7:TR?= NI[1V2QzPTN|NkmyOS=>
CNE-2 MYPGeY5kfGmxbjDBd5NigQ>? MknoNVAh|ryP NGXHW3E1QCCq MYjEUXNQ NXLrWJF7UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= MYCyOVM{Pjl{NR?=
HONE-1 NY\XdnprTnWwY4Tpc44hSXO|YYm= M{n1XlExKM7:TR?= NHW4e2o1QCCq MnP3SG1UVw>? NHW3SoNKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz MVqyOVM{Pjl{NR?=
NEC8 M1flNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T4PWlEPTB;MD6wPVY2OSEQvF2= MWfTRW5ITVJ?
P12-ICHIKAWA NUjrSVhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMUG2NkDPxE1? MlWxV2FPT0WU
MDA-MB-175-VII NWqzSFlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DOfGlEPTB;MD6xN|c{QCEQvF2= M3;3SHNCVkeHUh?=
AsPC-1 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL1TWM2OD1yLkKyNVIzKM7:TR?= Mo\iV2FPT0WU
T47D NUXmS3hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMkiyOUDPxE1? M3HUenNCVkeHUh?=
HH NXLrdmF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zl[mlEPTB;MD6zNFI5OyEQvF2= NV\ueHVWW0GQR1XS
MOLT-16 M1XteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnOSoQxUUN3ME2wMlMxOzJizszN M1nycXNCVkeHUh?=
ES5 MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTwT2NKSzVyPUCuN|Q1PTVizszN NXvCS|dXW0GQR1XS
RS4-11 NVL1O5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwM{S2NUDPxE1? NY\mbYNsW0GQR1XS
KARPAS-45 NG[zfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnjenZuUUN3ME2wMlM4OzJzIN88US=> NHfsSGVUSU6JRWK=
NCI-H720 NVqxV3NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLVUY1KSzVyPUCuN|c3PzlizszN NHTS[ZdUSU6JRWK=
H9 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorRTWM2OD1yLkO4PFg{KM7:TR?= MV3TRW5ITVJ?
EFM-19 M1T4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfjTWM2OD1yLkS0NFEh|ryP NInFOHpUSU6JRWK=
SBC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\TTWM2OD1yLkS0NFM2KM7:TR?= MknNV2FPT0WU
A4-Fuk NXvtZYdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHqd3pKSzVyPUCuOFY5PjhizszN NWTkZWJ1W0GQR1XS
NCI-H1563 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwNEixPFkh|ryP Ml23V2FPT0WU
HCC1419 NVPiW|lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLuTWM2OD1yLkS4PFkzKM7:TR?= NVvVUpRGW0GQR1XS
H-EMC-SS NGHs[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PwU2lEPTB;MD60PVk{QSEQvF2= NU\LfXpwW0GQR1XS
BHT-101 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLnTWM2OD1yLkWyPVYyKM7:TR?= MmHNV2FPT0WU
IGROV-1 NH;yUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL4cZd3UUN3ME2wMlU2OjR7IN88US=> MVvTRW5ITVJ?
HGC-27 NYHvcZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT1bW9PUUN3ME2wMlU3Pzh|IN88US=> MYfTRW5ITVJ?
MDA-MB-361 MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3qTWM2OD1yLkW3O|YyKM7:TR?= MnziV2FPT0WU
KE-37 NWTMV4NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjlO|FKSzVyPUCuOVgzPiEQvF2= NXXHNFJnW0GQR1XS
HCC70 NYj0cFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rwNGlEPTB;MD61PVgzPyEQvF2= MofvV2FPT0WU
LNCaP-Clone-FGC NHm3VnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\MTWM2OD1yLk[xNFQ5KM7:TR?= NH3XWZlUSU6JRWK=
HAL-01 NHy3ZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\jTWM2OD1yLk[yNVMh|ryP M4jJTHNCVkeHUh?=
HT MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zDfmlEPTB;MD62N|I{QSEQvF2= MmHnV2FPT0WU
MDA-MB-415 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X3dmlEPTB;MD62N|YzPiEQvF2= M3u3VnNCVkeHUh?=
NOS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLzbI9KSzVyPUCuOlM4OjNizszN MnXHV2FPT0WU
DU-145 MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHiT5hKSzVyPUCuOlQ4PDVizszN M{f5WHNCVkeHUh?=
OCUB-M NYfP[JZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jWcGlEPTB;MD63NFk3PiEQvF2= MVXTRW5ITVJ?
VA-ES-BJ MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7SZYxZUUN3ME2wMlc{ODJ3IN88US=> NUnwfFZQW0GQR1XS
J-RT3-T3-5 NFOwXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwN{S0NFMh|ryP MnqyV2FPT0WU
MOLT-4 M1LnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DB[2lEPTB;MD64NFU5OiEQvF2= NFXIfWdUSU6JRWK=
NB7 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHSVHJKSzVyPUCuPFI1OTFizszN M4\mWnNCVkeHUh?=
L-363 NH7JN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPEV29KSzVyPUCuPFM1PDJizszN NGDQVXNUSU6JRWK=
NKM-1 M2DhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3pfIRKSzVyPUCuPFYzPTNizszN MV7TRW5ITVJ?
HOP-92 NHzNZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvlTWM2OD1yLki3NlI{KM7:TR?= MULTRW5ITVJ?
OAW-42 M4TkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDPc5UyUUN3ME2wMlg5PzJizszN MmjlV2FPT0WU
HuO9 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwOUK3OVEh|ryP MWXTRW5ITVJ?
MFE-280 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S0S2lEPTB;MD65OlQ3PSEQvF2= M2LDc3NCVkeHUh?=
EM-2 NIi4N|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XoVmlEPTB;MD65O|k{QSEQvF2= NFj1S5pUSU6JRWK=
NCI-H520 NEftWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3DTWM2OD1yLkm4OVkzKM7:TR?= MljlV2FPT0WU
LB2241-RCC MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvRXGFwUUN3ME2wMlk6PzN2IN88US=> MnHUV2FPT0WU
SK-NEP-1 Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP3WI5mUUN3ME2xMlE1PDh3IN88US=> M32xW3NCVkeHUh?=
LXF-289 NFfSNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVexXIEyUUN3ME2xMlE4OTV4IN88US=> M4LQT3NCVkeHUh?=
EPLC-272H NX\UPZpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\0OWlEPTB;MT6xO|I2PiEQvF2= NFvSe|JUSU6JRWK=
COLO-684 NWDXU3pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;aeWpKSzVyPUGuNlM4OjVizszN NHu0VIVUSU6JRWK=
ES1 NYe2fHBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\Ienl5UUN3ME2xMlI1ODZ3IN88US=> MYDTRW5ITVJ?
DOHH-2 NXLnPW1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XB[GlEPTB;MT6yPFIxOyEQvF2= NULx[JRTW0GQR1XS
CTB-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrlPXFKSzVyPUGuNlg6QSEQvF2= MXLTRW5ITVJ?
G-401 NV7lZo5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTsTWM2OD1zLkK5O|k2KM7:TR?= NVrnVYRnW0GQR1XS
LoVo M3LzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwM{K1N|Qh|ryP MUXTRW5ITVJ?
Ramos-2G6-4C10 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHYTWM2OD1zLkOzO|AyKM7:TR?= NFHYTYNUSU6JRWK=
MFM-223 NULXNoRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwM{S0OlEh|ryP MVHTRW5ITVJ?
PA-1 MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO2TWM2OD1zLkO1NlY2KM7:TR?= MofaV2FPT0WU
697 NGT1e4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD3V41KSzVyPUGuN|c3OTZizszN NGPYSWxUSU6JRWK=
QIMR-WIL M1vnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrCTWM2OD1zLkS5NVE3KM7:TR?= MnLsV2FPT0WU
HOS MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPWNmJ3UUN3ME2xMlQ6PTV6IN88US=> MYXTRW5ITVJ?
DMS-273 NH;6XJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfNT5JVUUN3ME2xMlUyQTV7IN88US=> NH;aRXFUSU6JRWK=
ME-180 M2PTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGwTWM2OD1zLkW2PFkyKM7:TR?= MULTRW5ITVJ?
HCC2218 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK1ZZBKSzVyPUGuOlgzOjVizszN M{\hc3NCVkeHUh?=
CAL-54 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnpN45NUUN3ME2xMlcyOjR{IN88US=> NFrUVGdUSU6JRWK=
OMC-1 M2n1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ThNGlEPTB;MT63OFY4PyEQvF2= MWTTRW5ITVJ?
COR-L105 NVj4PXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFwN{m3N|ch|ryP NUK2SIZDW0GQR1XS
BV-173 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXjTWM2OD1zLkixNFc1KM7:TR?= MWrTRW5ITVJ?
RKO NVXmNpFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULxboJRUUN3ME2xMlg4OTBzIN88US=> NGjLZ4dUSU6JRWK=
SNU-387 NHL3TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD1WnhOUUN3ME2xMlg5PDB4IN88US=> MYDTRW5ITVJ?
SW1088 NIrQPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwOUS2NFYh|ryP MULTRW5ITVJ?
Hs-578-T MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJwMUG0N|Mh|ryP NEjlVY5USU6JRWK=
OC-314 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\5TWM2OD1{LkG1NFg3KM7:TR?= NGDnOJJUSU6JRWK=
RMG-I NX32coZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;0d3JKSzVyPUKuNVY{QThizszN MoW1V2FPT0WU
NCI-H1395 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLJTWM2OD1{LkG4NFkyKM7:TR?= MYjTRW5ITVJ?
GAMG MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLwdIdQUUN3ME2yMlI{QDR3IN88US=> MlzJV2FPT0WU
LB1047-RCC NV;MelBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\me3RrUUN3ME2yMlI1OzF5IN88US=> NEiwS|ZUSU6JRWK=
MN-60 M{PWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJwMkm5NlMh|ryP MULTRW5ITVJ?
OAW-28 M4TaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTyTWM2OD1{LkK5PVUyKM7:TR?= NILkTWlUSU6JRWK=
NCI-H2228 NYfFR4FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJwM{G1OVIh|ryP MX3TRW5ITVJ?
ABC-1 M37aTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDRTWM2OD1{LkOzNlU{KM7:TR?= MoPUV2FPT0WU
LS-513 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n1emlEPTB;Mj6zN|Q5PCEQvF2= NFzQ[4RUSU6JRWK=
KS-1 NFWyW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV31NXlxUUN3ME2yMlM5OTlzIN88US=> MXzTRW5ITVJ?
NB69 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTsXGdqUUN3ME2yMlM5QTh|IN88US=> M1jVeHNCVkeHUh?=
VM-CUB-1 NYDoTGFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrKPYJjUUN3ME2yMlM6ODh|IN88US=> NEH4flNUSU6JRWK=
D-423MG NUHGcnJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJwNEGwOFQh|ryP NETHe2pUSU6JRWK=
EW-18 NVu2b|lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJwNEG5N|kh|ryP NFfPbIhUSU6JRWK=
YH-13 M3;ROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G5SGlEPTB;Mj60OlE2OyEQvF2= NV3HWWdzW0GQR1XS
T-24 M3XVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDSVZB1UUN3ME2yMlQ4QDhzIN88US=> MVXTRW5ITVJ?
ES8 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Sy[WlEPTB;Mj60PVI5PyEQvF2= NFnBWGhUSU6JRWK=
ES3 NVP5c2xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\tTYVKSzVyPUKuOFk4PTlizszN NXjmT|ZrW0GQR1XS
RXF393 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jTU2lEPTB;Mj62NFQ5PyEQvF2= M1fQS3NCVkeHUh?=
RPMI-8226 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\NTWM2OD1{Lk[yPVU{KM7:TR?= MkfaV2FPT0WU
AGS Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y5VGlEPTB;Mj63NlE{PyEQvF2= M3K2fnNCVkeHUh?=
HCC1395 NFzRRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqxTWM2OD1{Lke1NVg4KM7:TR?= MkTnV2FPT0WU
MV-4-11 NV;veGV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJwN{WyOlYh|ryP NH:0PWlUSU6JRWK=
A204 NH[2U45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSyTWM2OD1{LkizPFczKM7:TR?= M4PRSHNCVkeHUh?=
MCF7 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[ySVJrUUN3ME2yMlg3OTF5IN88US=> MXHTRW5ITVJ?
SNU-423 NVjwZ|c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HOVGlEPTB;Mj64PVI1OiEQvF2= MW\TRW5ITVJ?
NCI-H1048 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJwOU[4OlUh|ryP Ml;XV2FPT0WU
GR-ST NWjwVVMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDiZ4toUUN3ME2zMlA1PjFzIN88US=> MkXOV2FPT0WU
EoL-1- NUe4U3FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfjenJKSzVyPUOuNFcxPThizszN MXrTRW5ITVJ?
HuH-7 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Vbo45UUN3ME2zMlA6PDZ2IN88US=> NVrnVY9sW0GQR1XS
OS-RC-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn4WIpbUUN3ME2zMlEyOTlizszN MV;TRW5ITVJ?
EW-3 NYDISW85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvxTWM2OD1|LkG5OVI6KM7:TR?= M2rXTXNCVkeHUh?=
NCI-H747 NF[3OllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HWXGlEPTB;Mz6yNFY6PCEQvF2= NYT3SFhMW0GQR1XS
EW-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7nfHJyUUN3ME2zMlIyQDd7IN88US=> NGDQcGVUSU6JRWK=
DOK MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjxdHVKSzVyPUOuNlI5PTlizszN M3nIc3NCVkeHUh?=
HCC2157 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNwM{ixO|kh|ryP MYnTRW5ITVJ?
OVCAR-3 NITneXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTNwNEC3PFYh|ryP MW\TRW5ITVJ?
NCI-H1623 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTNwNEGyNlQh|ryP NVj2Xng2W0GQR1XS
H4 M2Tk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNwNEW2NlYh|ryP M4\JPXNCVkeHUh?=
SW1710 M4D6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fo[GlEPTB;Mz60OlY4QCEQvF2= MUDTRW5ITVJ?
RT-112 M1;zUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7hTGFKSzVyPUOuOVI{QDhizszN MlnMV2FPT0WU
DMS-114 NGe1XI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\qNmlEPTB;Mz62NlI4QCEQvF2= MVLTRW5ITVJ?
AN3-CA MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXKXFI5UUN3ME2zMlYzPDV4IN88US=> MYLTRW5ITVJ?
KNS-62 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D6O2lEPTB;Mz62N|M{QCEQvF2= MYfTRW5ITVJ?
SJRH30 NFnxN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrFTWM2OD1|Lk[5NVIzKM7:TR?= NYLmUWxmW0GQR1XS
G-402 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjFPIhIUUN3ME2zMlcxPzFzIN88US=> Mk\6V2FPT0WU
MHH-PREB-1 M3jNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37kUGlEPTB;Mz63NlA{QCEQvF2= MV7TRW5ITVJ?
P30-OHK MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\MVHFSUUN3ME2zMlgxQTd4IN88US=> NHrtNXdUSU6JRWK=
RVH-421 M1zXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PibmlEPTB;Mz64NVc5QCEQvF2= MUHTRW5ITVJ?
LU-134-A NHHteZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPVb2N2UUN3ME2zMlg5PDJ6IN88US=> M{\Yc3NCVkeHUh?=
ECC10 NFrLNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHRS5Q1UUN3ME2zMlk{PjJ{IN88US=> M3PZSnNCVkeHUh?=
TGW M1Wzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;vfYlKSzVyPUSuNFI{ODVizszN NX20VVhqW0GQR1XS
MLMA NE\xPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\BTWM2OD12LkCyPVY3KM7:TR?= MUHTRW5ITVJ?
SCC-25 Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTRwME[1OlYh|ryP MlT3V2FPT0WU
TYK-nu MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DRdmlEPTB;ND6wPVU{PCEQvF2= M2C5dXNCVkeHUh?=
LAMA-84 M4[x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrVTWM2OD12LkG0NVkyKM7:TR?= M{fGR3NCVkeHUh?=
Calu-3 NEHWSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTRwMkS0NVYh|ryP MkHmV2FPT0WU
NCI-H460 M3fUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLGZ3FKSzVyPUSuNlY1PDNizszN NHLQR3JUSU6JRWK=
EGI-1 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTRwM{e3O|gh|ryP MWnTRW5ITVJ?
NCI-H292 M4DaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr1TWM2OD12LkO4NVQ3KM7:TR?= NIjKTYZUSU6JRWK=
HCE-T MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRwNEG1O|kh|ryP MmDnV2FPT0WU
EW-11 NWTSZpEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e0bmlEPTB;ND60NVg{QCEQvF2= NH3N[JBUSU6JRWK=
ATN-1 M1LDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRwNESzNFQh|ryP NWXuS|Y3W0GQR1XS
NB5 M{TqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrvSVlYUUN3ME20MlU{Pjl5IN88US=> NHvYTVZUSU6JRWK=
KLE MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwN{CxPVgh|ryP M3;5W3NCVkeHUh?=
CAL-39 Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDyTWM2OD12LkeyNVQ3KM7:TR?= NVLPXmJVW0GQR1XS
TI-73 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTRwOEC2NFkh|ryP NYXjVXNLW0GQR1XS
HO-1-N-1 M3SyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXBTWM2OD12Lkm0NkDPxE1? NXn0bXFlW0GQR1XS
786-0 NIraS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXCTWM2OD12Lkm0Olc{KM7:TR?= M2LPSnNCVkeHUh?=
SK-N-DZ NGTEW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVraRZRKUUN3ME20Mlk3OTR{IN88US=> M4LPbXNCVkeHUh?=
NCI-H446 MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHNPHVjUUN3ME21MlIxODB7IN88US=> MWHTRW5ITVJ?
ETK-1 NEL4WnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTMb286UUN3ME21MlIyOTZ3IN88US=> NGLzS|lUSU6JRWK=
BT-20 NE\WNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rEeGlEPTB;NT6yNVM2OyEQvF2= MVHTRW5ITVJ?
MEL-HO M1\Q[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CyTmlEPTB;NT6zO|M{PiEQvF2= MXrTRW5ITVJ?
CAL-27 MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTVwNE[zN|kh|ryP M2T3enNCVkeHUh?=
SW872 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojFTWM2OD13LkW5OFI5KM7:TR?= NFfSOZVUSU6JRWK=
RPMI-2650 M1\ocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWyTWM2OD13Lk[2NVk6KM7:TR?= M2fU[HNCVkeHUh?=
PFSK-1 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjGRoxKSzVyPUWuO|I4OzJizszN MV3TRW5ITVJ?
SF295 M3;nTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TW[mlEPTB;NT64NFY{OyEQvF2= MXzTRW5ITVJ?
Becker NEHaO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG2Tnk{UUN3ME21Mlg3PDd{IN88US=> NELyOHlUSU6JRWK=
Saos-2 NVvSbFFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDXTWM2OD13Lki2OVMh|ryP Mo\qV2FPT0WU
SK-OV-3 M3\yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[xO2lEPTB;NT65PVgyPiEQvF2= M4Ty[XNCVkeHUh?=
VMRC-RCZ M{fBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTZwMEi3O|Mh|ryP NYmyVJZNW0GQR1XS
EW-22 NF;UV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLGTWM2OD14LkG5OlQ6KM7:TR?= Moj2V2FPT0WU
BT-474 NHTBS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITLcYtKSzVyPU[uNlM{KM7:TR?= NH3HOJNUSU6JRWK=
BFTC-909 M2jVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;HeHFKSzVyPU[uN|A{PDVizszN MXrTRW5ITVJ?
NB12 MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P4T2lEPTB;Nj6zPVA4OSEQvF2= Ml;0V2FPT0WU
D-263MG MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXlTWM2OD14LkS1NVY6KM7:TR?= MXTTRW5ITVJ?
SNB75 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LFRmlEPTB;Nj62NFE1OyEQvF2= NIfIc45USU6JRWK=
A704 NGjlb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwNkOwOkDPxE1? M1jIR3NCVkeHUh?=
NCI-H1693 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jDNGlEPTB;Nj62N|YxPCEQvF2= M4HZfHNCVkeHUh?=
LN-405 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjacpZKSzVyPU[uO|k3PzJizszN NWD2WId2W0GQR1XS
CHL-1 NV7RNHhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HYUWlEPTB;Nj64NFA4QSEQvF2= M4r2VHNCVkeHUh?=
A498 NYqyWFlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP2TG1KSzVyPU[uPFE6PjFizszN NX7r[Y9RW0GQR1XS
TE-12 M2LtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XEVGlEPTB;Nj64N|gyPyEQvF2= NGTVfIVUSU6JRWK=
TE-6 NWrSU3QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTZwOUOwN|gh|ryP MV\TRW5ITVJ?
AU565 NIr0VmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTZwOU[5OVch|ryP NW\OcY05W0GQR1XS
RD MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;MbGlEPTB;Nj65PFI5PCEQvF2= MYDTRW5ITVJ?
SW1463 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGyVlg6UUN3ME23MlEyOTZ6IN88US=> NEHxNnJUSU6JRWK=
LU-99A M{jXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTdwMUSzNlIh|ryP NX;uVIl7W0GQR1XS
NCI-H28 NFjQZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT3WW5KSzVyPUeuNlkzPCEQvF2= NGTMW5JUSU6JRWK=
MC-IXC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLBSlFrUUN3ME23MlQ5PTd4IN88US=> MoPOV2FPT0WU
GP5d MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfFOJBPUUN3ME23MlQ5PzZ2IN88US=> MWTTRW5ITVJ?
GB-1 NXr3bopzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jCemlEPTB;Nz61OFgxPCEQvF2= MV3TRW5ITVJ?
CAL-33 MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XtSmlEPTB;Nz62OlI{OyEQvF2= MUjTRW5ITVJ?
MSTO-211H NEK1VpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrNUnJKSzVyPUeuOlc{OzZizszN MkP6V2FPT0WU
TE-5 NVntSYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEThN3VKSzVyPUeuO|k{OzRizszN M3jaTXNCVkeHUh?=
D-566MG Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzqV21KSzVyPUiuNFQ1OjlizszN MX7TRW5ITVJ?
JVM-3 NHnQPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf1TWM2OD16LkG1NlY5KM7:TR?= M1HiO3NCVkeHUh?=
T98G NF\aV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS4W2tKSzVyPUiuNVgxPjdizszN NHj6N4dUSU6JRWK=
HCC1954 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV23OGFSUUN3ME24MlQ2OTB2IN88US=> NUHGNphVW0GQR1XS
SF126 NU\PemJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TObmlEPTB;OD60OVk{PiEQvF2= MUTTRW5ITVJ?
LB996-RCC NVzmU5czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TlfGlEPTB;OD61N|I2PyEQvF2= M17IZXNCVkeHUh?=
SKG-IIIa NWfDPGtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonFTWM2OD16Lk[zNFY6KM7:TR?= MV3TRW5ITVJ?
NCI-SNU-1 M13KW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf4XVFKSzVyPUiuOlQ3PDNizszN MYjTRW5ITVJ?
LB771-HNC NEntWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRThwNkS2PVYh|ryP NF\J[5RUSU6JRWK=
SCC-4 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvUUHhFUUN3ME24MlY5OjF7IN88US=> NU\NWGt[W0GQR1XS
CAMA-1 M37PNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm4bmNkUUN3ME24Mlc4OTR4IN88US=> M3ftbHNCVkeHUh?=
D-502MG NHjCVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jORmlEPTB;OD63PFYzQSEQvF2= MWTTRW5ITVJ?
ESS-1 NF70N|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rYSmlEPTB;OD64PFcxPCEQvF2= NIrnbXhUSU6JRWK=
HEC-1 NXvvRppHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TaRWlEPTB;OD64PVg3PiEQvF2= MoTQV2FPT0WU
NB10 NEL4XZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLpPJpxUUN3ME25MlAzOjJ2IN88US=> NGO4XIdUSU6JRWK=
8505C M3PIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXRTWM2OD17LkC0NlMzKM7:TR?= NGrn[I9USU6JRWK=
EFO-27 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrsUmhKUUN3ME25MlE3PDF{IN88US=> NFrWOHhUSU6JRWK=
HN Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7jWYtKSzVyPUmuNVY3OjhizszN NED1fnVUSU6JRWK=
DSH1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG2PYxnUUN3ME25MlIxQDdizszN NF7V[lNUSU6JRWK=
NBsusSR MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrTTWM2OD17LkK3OFAzKM7:TR?= NXrzTYJ1W0GQR1XS
LS-123 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTlwM{G3OlEh|ryP NFjQ[5JUSU6JRWK=
SHP-77 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTlwM{m5N|Uh|ryP MoD0V2FPT0WU
ACN M{P0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDZO5NKSzVyPUmuOVMzPzdizszN NYHUV|JMW0GQR1XS
U251 M4nSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3JcGNKSzVyPUmuOlU2PDRizszN NGHM[FRUSU6JRWK=
A431 M3i1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTlwOECyN|gh|ryP NYDlRVl7W0GQR1XS
5637 NYjo[3pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDGTWM2OD17Lki0PVg1KM7:TR?= NXPRU3ZtW0GQR1XS
MDA-MB-157 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XhWWlEPTB;OT65Nlg4QCEQvF2= M1HTfXNCVkeHUh?=
A101D NH7zOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjxWpUzUUN3ME25Mlk6QTd2IN88US=> MX;TRW5ITVJ?
YKG-1 Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXrc5NKSzVyPUGwMlIxODZizszN NEOwSWFUSU6JRWK=
LAN-6 MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXGTWM2OD1zMD6yNVY1KM7:TR?= M3\YT3NCVkeHUh?=
OVCAR-5 NX\PWJBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13HU2lEPTB;MUCuNlQ{OyEQvF2= M4P6cnNCVkeHUh?=
A549 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjYTXBKSzVyPUGwMlM6PzNizszN M1PwSHNCVkeHUh?=
no-11 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFyLkSzOVMh|ryP Mo\zV2FPT0WU
SF539 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[4TWM2OD1zMD65NFQyKM7:TR?= MXPTRW5ITVJ?
A388 NWXp[HUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64NnU1UUN3ME2xNU4{QDl5IN88US=> NYf3foNnW0GQR1XS
DEL NXf3b5pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjzV3FKSzVyPUGxMlQzPCEQvF2= MYLTRW5ITVJ?
SW954 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXTXnBKSzVyPUGxMlQ3PjhizszN Mmr4V2FPT0WU
TK10 NWjBSo1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFzLkWyO|Eh|ryP NX\Wc4FVW0GQR1XS
SW756 M3:yOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rHV2lEPTB;MUGuOVI6PCEQvF2= M4S2dHNCVkeHUh?=
PC-3 NVnp[IdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvK[3RlUUN3ME2xNU42PzZ2IN88US=> Ml[5V2FPT0WU
ONS-76 NUHpemJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETGbY5KSzVyPUGxMlY{PiEQvF2= NEizRZdUSU6JRWK=
A427 MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvlUJVSUUN3ME2xNU44ODl|IN88US=> MVjTRW5ITVJ?
MEG-01 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFzLke1NFkh|ryP MXXTRW5ITVJ?
BB30-HNC MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFzLke5PFIh|ryP Mn;yV2FPT0WU
NCI-H1299 NGnBeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f0d2lEPTB;MUGuPFA6OyEQvF2= NECxOJJUSU6JRWK=
GCT M3vkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDhZmpCUUN3ME2xNU45OjJ6IN88US=> MUfTRW5ITVJ?
D-247MG NIrEcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\5dIlkUUN3ME2xNU46PjZ|IN88US=> M1XXRXNCVkeHUh?=
CFPAC-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITq[ZhKSzVyPUGxMlk4QDJizszN MmCyV2FPT0WU
EKVX NV\q[odxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17qfWlEPTB;MUKuNFMyOyEQvF2= MVHTRW5ITVJ?
CAL-51 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfIZpF[UUN3ME2xNk4xPzF4IN88US=> M4r3cXNCVkeHUh?=
BB49-HNC M3r5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7OTWM2OD1zMj6xNVc4KM7:TR?= NV[4bGQxW0GQR1XS
RPMI-7951 NVLZ[Zp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX1TWM2OD1zMj6xPFU1KM7:TR?= NEXYTpdUSU6JRWK=
RH-1 NUGzOoN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF{LkKxPFQh|ryP MXvTRW5ITVJ?
BCPAP NVSyNpF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLUPJh{UUN3ME2xNk41PzR7IN88US=> MWTTRW5ITVJ?
GCIY MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPQWFZ[UUN3ME2xNk42OjB7IN88US=> MXfTRW5ITVJ?
KNS-81-FD NHjUSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF{LkW4Olkh|ryP NIC2SItUSU6JRWK=
KYSE-140 NHfQfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[5RlJKSzVyPUGyMlg2QTVizszN Mn:2V2FPT0WU
Ca-Ski MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jvPWlEPTB;MUKuPVA1OSEQvF2= MVHTRW5ITVJ?
TGBC1TKB MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLPeHE{UUN3ME2xNk46OTF3IN88US=> NFzTWWhUSU6JRWK=
HCC1187 M1;CZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG4cIRKSzVyPUGzMlE6OTJizszN MUTTRW5ITVJ?
SJSA-1 NHHPWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP3XWdKSzVyPUGzMlI{OjdizszN M2ewSHNCVkeHUh?=
CTV-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLpR|Z{UUN3ME2xN{4{PDVizszN NXPBS2xSW0GQR1XS
WM-115 NYL4UJhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MornTWM2OD1zMz62OFg{KM7:TR?= MXjTRW5ITVJ?
CHP-212 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoryTWM2OD1zMz65O|M6KM7:TR?= MWTTRW5ITVJ?
SCC-15 NHqzTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly1TWM2OD1zMz65O|c2KM7:TR?= NGPlXYVUSU6JRWK=
BPH-1 M{DpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDM[HpSUUN3ME2xOE4yPjZ2IN88US=> NV7BOXFUW0GQR1XS
SW780 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPlNFVZUUN3ME2xOE42ODJ3IN88US=> MX;TRW5ITVJ?
NCI-H2291 M1js[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PMZmlEPTB;MUSuOVg4QCEQvF2= M1LSN3NCVkeHUh?=
JEG-3 NUH6NHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF2Lk[zNlYh|ryP MX\TRW5ITVJ?
CAL-120 NWfzNVVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1riRmlEPTB;MUSuO|AzPyEQvF2= M2nU[3NCVkeHUh?=
NCI-H23 NYfjVnNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnrRnN7UUN3ME2xOE44QTl5IN88US=> NVLpWINUW0GQR1XS
MS-1 NFvic2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nEO2lEPTB;MUSuPVYyOSEQvF2= MYXTRW5ITVJ?
PC-14 M4TOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXF[G0yUUN3ME2xOE46PjV2IN88US=> M{DtZnNCVkeHUh?=
D-283MED MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLuTWM2OD1zNT6wNVEyKM7:TR?= NVL6VmVzW0GQR1XS
OE19 NIf3S3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Ly[mlEPTB;MUWuNVU1OSEQvF2= NHfB[2pUSU6JRWK=
CAS-1 NES5e4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLv[HZGUUN3ME2xOU41OTh2IN88US=> MnfqV2FPT0WU
NCI-H727 M{Ti[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi1TWM2OD1zNT60NlIyKM7:TR?= NFTOUnVUSU6JRWK=
SiHa NIDlZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvPWnZyUUN3ME2xOU44PTl2IN88US=> NFy1TlBUSU6JRWK=
BFTC-905 NYPFXpR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF3Lke2PVQh|ryP M{SyV3NCVkeHUh?=
MDA-MB-453 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF4LkG2OFIh|ryP MoXDV2FPT0WU
HuP-T3 NEHM[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPyN2pKSzVyPUG2MlY{PzNizszN NVzCdpRWW0GQR1XS
SK-LU-1 M2TxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXkSZpKSzVyPUG2MlY6PTZizszN NX7JNWx5W0GQR1XS
Detroit562 M33Yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPqW3NKSzVyPUG2Mlc{OThizszN MVvTRW5ITVJ?
HCC1569 M3y3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLNTWM2OD1zNj64N|M4KM7:TR?= MkCwV2FPT0WU
SK-MES-1 NEnkUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm0[FFKSzVyPUG2Mlg1OTlizszN NV;ISYJuW0GQR1XS
BB65-RCC NVi1cnlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTUTWM2OD1zNz6wOFc6KM7:TR?= MX\TRW5ITVJ?
LOXIMVI M3vYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfLb4s2UUN3ME2xO{4xPzB5IN88US=> NVj6fYZ7W0GQR1XS
SW1783 NXvBZ|VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDIXmxPUUN3ME2xO{4yOjhizszN MVzTRW5ITVJ?
NH-12 NX\6T|FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF5LkOzNFMh|ryP NUSz[2xYW0GQR1XS
UACC-257 NWnuO4hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHkc45KSzVyPUG3MlU2OTJizszN MYrTRW5ITVJ?
KOSC-2 NEXFOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofkTWM2OD1zNz62O|U4KM7:TR?= MnL5V2FPT0WU
KG-1 MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF5Lk[5N|ch|ryP NVKxeFVxW0GQR1XS
M059J NYK4cnJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF5LkewN{DPxE1? MWXTRW5ITVJ?
MHH-NB-11 M4HCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XBd2lEPTB;MUeuPVY4OyEQvF2= MVzTRW5ITVJ?
EW-1 M2rCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF6LkGzPFIh|ryP NEHMTnFUSU6JRWK=
CAL-85-1 NEjQXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF6LkKzOVch|ryP MVnTRW5ITVJ?
639-V MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELkWVhKSzVyPUG4MlM{PTRizszN Mo\aV2FPT0WU
C32 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF6LkS3Nlch|ryP NXTzfHFPW0GQR1XS
KM-H2 M4jrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnLTWM2OD1zOD61NlMzKM7:TR?= MkXyV2FPT0WU
A253 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v3e2lEPTB;MUiuO|I5PiEQvF2= Mlm4V2FPT0WU
NCI-N87 NF\F[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXpSmd5UUN3ME2xPE46ODB6IN88US=> Mo\JV2FPT0WU
8-MG-BA MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECxUoFKSzVyPUG5MlA3PDZizszN MWrTRW5ITVJ?
GI-ME-N NVPwOpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;KR3FKSzVyPUG5MlE2PDZizszN NVzKZZpmW0GQR1XS
8305C NUTTZZdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TOOGlEPTB;MUmuNlI5PiEQvF2= NV7aVlZuW0GQR1XS
TE-8 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DJW2lEPTB;MUmuN|AzPCEQvF2= MmnQV2FPT0WU
KYSE-270 NH;1V4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\KTWM2OD1{MD6wNlE4KM7:TR?= MXvTRW5ITVJ?
HL-60 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17DTWlEPTB;MkCuNFk1OSEQvF2= NHvrRYFUSU6JRWK=
Mo-T NHPIeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPsNpVkUUN3ME2yNE4yPjZ3IN88US=> M375SXNCVkeHUh?=
NCI-H1355 M3q1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\JO45KSzVyPUKwMlM{PzRizszN M4nrTXNCVkeHUh?=
HT-1080 MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\6TWM2OD1{MD61OFk4KM7:TR?= MnvMV2FPT0WU
MIA-PaCa-2 NWXvPWlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrGTWM2OD1{MD62PFg{KM7:TR?= NGm4[Y9USU6JRWK=
NCI-H441 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJyLkezO|kh|ryP Mn3lV2FPT0WU
LCLC-97TM1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPRTWM2OD1{MD64NVM1KM7:TR?= MYXTRW5ITVJ?
HT-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHQ[4pKSzVyPUKxMlU3OzFizszN NH:3N5dUSU6JRWK=
22RV1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrpR3ZMUUN3ME2yNU42Pjh3IN88US=> MnHmV2FPT0WU
LK-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjmWJNKSzVyPUKxMlU6PTNizszN M1PscXNCVkeHUh?=
CW-2 M4jX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3GSpJKSzVyPUKxMlYxPjlizszN NIXlcXJUSU6JRWK=
KYSE-510 NUP1b5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYiy[pp5UUN3ME2yNU43ODl3IN88US=> NX7mN4dIW0GQR1XS
CGTH-W-1 M2DFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P3cWlEPTB;MkGuO|E3PiEQvF2= NFiyUoFUSU6JRWK=
NCI-H661 NYjheGxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHQflFKSzVyPUKyMlA{PCEQvF2= NYGwbFRnW0GQR1XS
KU-19-19 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ{LkG2PVch|ryP MknQV2FPT0WU
NCI-H2122 NV3MZndUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJ{LkK0N|Ih|ryP NXnX[JdQW0GQR1XS
NCI-H526 NHPE[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ{LkO4PVUh|ryP M17YT3NCVkeHUh?=
NCI-H1650 NI[0fHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn5XFNKSzVyPUKyMlc3PCEQvF2= MVzTRW5ITVJ?
AM-38 M3XY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3Je4lRUUN3ME2yNk45Pjh7IN88US=> MW\TRW5ITVJ?
NCI-H2405 NGfKTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ|LkK1N|Mh|ryP NYPJWnV4W0GQR1XS
M14 NX7hdWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7nTWM2OD1{Mz60NFg5KM7:TR?= NFPqVZdUSU6JRWK=
ES4 MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXLTWM2OD1{Mz60NlMzKM7:TR?= NX\qOpRyW0GQR1XS
DJM-1 M4XlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjSTWM2OD1{Mz61NlM1KM7:TR?= Mnn5V2FPT0WU
S-117 Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ|Lke2OVEh|ryP NUPrRo9TW0GQR1XS
MZ2-MEL M{HRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS5VYp4UUN3ME2yN{44PzV7IN88US=> MVjTRW5ITVJ?
SK-MEL-2 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofpTWM2OD1{Mz64NVM{KM7:TR?= NGfSe5FUSU6JRWK=
HCC1806 NHPLTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOwUHBKSzVyPUKzMlg4ODlizszN NGDHS2VUSU6JRWK=
NMC-G1 NEe0UpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJ2LkKyNlYh|ryP NXqzdGVFW0GQR1XS
DK-MG MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ2LkK5OEDPxE1? NHHpcIVUSU6JRWK=
SK-N-FI MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ2LkOzNFIh|ryP MXLTRW5ITVJ?
KINGS-1 NVj6NHZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ2LkS4O|Qh|ryP M1exb3NCVkeHUh?=
HCC2998 MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomwTWM2OD1{ND60PFg2KM7:TR?= NUjucnlWW0GQR1XS
ALL-PO MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjYRoNvUUN3ME2yOE43OTlizszN NIexcnZUSU6JRWK=
MPP-89 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPKTWM2OD1{NT6wOFU5KM7:TR?= NFqzfHZUSU6JRWK=
NCI-H2342 NGL4b2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ3LkG5OVMh|ryP M3jKVXNCVkeHUh?=
TE-1 NUnyR2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ3LkO1OlMh|ryP NFXVcZJUSU6JRWK=
RH-18 M12y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJ3LkW5NVgh|ryP MnPmV2FPT0WU
HT-1376 NHe0U2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ3Lk[0OlUh|ryP M{XQdXNCVkeHUh?=
U-2-OS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHsTWM2OD1{NT62PFg5KM7:TR?= M4noUnNCVkeHUh?=
BT-549 M3rJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ3LkmwNVEh|ryP NXXlbFF6W0GQR1XS
NCI-H1755 M1q5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL6TWM2OD1{NT65PVQ2KM7:TR?= NXnrcpd[W0GQR1XS
EW-13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f0ZmlEPTB;Mk[uNFI4PCEQvF2= NIP6[4NUSU6JRWK=
NB13 NIfhU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJ4LkC5OFkh|ryP NHTwfXlUSU6JRWK=
NUGC-3 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH0TWM2OD1{Nj6yNVA{KM7:TR?= M125bXNCVkeHUh?=
GMS-10 NYHXNmNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHjfWJHUUN3ME2yOk4zOzV|IN88US=> NVzacWZLW0GQR1XS
CHP-134 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr0OmVmUUN3ME2yOk4{QDZ5IN88US=> M17DVnNCVkeHUh?=
SW962 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjGOJBKSzVyPUK2MlUxOjFizszN MnfMV2FPT0WU
SNU-449 M1nmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DvcGlEPTB;MkeuNFgxOyEQvF2= NGm5N4pUSU6JRWK=
HuP-T4 M1:2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljQTWM2OD1{Nz6wPFc6KM7:TR?= MVvTRW5ITVJ?
SW948 NGHVVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqxXppHUUN3ME2yO{4yOzR2IN88US=> MlXhV2FPT0WU
NCI-H226 MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLtTWM2OD1{Nz60OVc5KM7:TR?= NEnlNGRUSU6JRWK=
SK-PN-DW MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\acXVUUUN3ME2yO{43ODF{IN88US=> NHXjeolUSU6JRWK=
GI-1 MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ5LkeyNUDPxE1? MVjTRW5ITVJ?
CAL-12T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESzVYFKSzVyPUK4MlEyOTJizszN NX\3bndIW0GQR1XS
YAPC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3zTWM2OD1{OD6yOVY1KM7:TR?= MVzTRW5ITVJ?
SNU-C2B MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ6LkK5OlQh|ryP MU\TRW5ITVJ?
RCC10RGB M3i5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjKOZRKSzVyPUK4MlU1OTdizszN M2XJV3NCVkeHUh?=
ES7 M1Xs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jvcmlEPTB;MkmuNVQ3PSEQvF2= NELkWZpUSU6JRWK=
PANC-03-27 NV72UnlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrSWZhmUUN3ME2yPU41PDRizszN NXr3XoNlW0GQR1XS
ES6 NYPpNYdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHkRm54UUN3ME2yPU45OTV5IN88US=> NUPiRVZ[W0GQR1XS
HT-1197 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\FV2lEPTB;M{CuNFU6QCEQvF2= NETkXIJUSU6JRWK=
ZR-75-30 NIW5T3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTsPY5KSzVyPUOwMlI{QDNizszN M3HZe3NCVkeHUh?=
DB NGXQRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNyLkS5OFIh|ryP MkHVV2FPT0WU
OCI-AML2 NGDINXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13HNmlEPTB;M{GuNFY6KM7:TR?= M3fvOnNCVkeHUh?=
NCI-H2170 MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLSepY4UUN3ME2zNU45PTF4IN88US=> M{\VNHNCVkeHUh?=
IST-MES1 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTN{LkK4PVch|ryP NIW2c4RUSU6JRWK=
769-P MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELabWhKSzVyPUOyMlM3PDFizszN MVLTRW5ITVJ?
COR-L23 M{TKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3OTWM2OD1|Mj65NFc{KM7:TR?= NGfIc4FUSU6JRWK=
SW626 NFv0NVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTN|LkG3O|Yh|ryP M3jsUHNCVkeHUh?=
LU-139 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDnTWM2OD1|Mz62OlA2KM7:TR?= M2f6cnNCVkeHUh?=
HT-144 M1K1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTiXFhKSzVyPUOzMlg3OyEQvF2= MnW0V2FPT0WU
CaR-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLpdYtJUUN3ME2zN{46QDJ{IN88US=> NUXZfGdrW0GQR1XS
OE33 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL1R41KSzVyPUO0MlI5PTVizszN M3K5OnNCVkeHUh?=
COLO-800 M3TuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTN2LkO2OFch|ryP NEK1bpNUSU6JRWK=
NB14 NVTWVlhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTN2LkS2PFQh|ryP NID4eVdUSU6JRWK=
KURAMOCHI M3\De2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTN4LkGxPVgh|ryP M3LiWXNCVkeHUh?=
SW48 NEnTOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HwdGlEPTB;M{[uNlQ4PCEQvF2= MUfTRW5ITVJ?
Daoy Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHPOIpKSzVyPUO2MlY2OzhizszN MmH5V2FPT0WU
TGBC24TKB M1ixNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTN4Lk[3JO69VQ>? NXXLVItMW0GQR1XS
DU-4475 NWn2cYFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXFTWM2OD1|Nj65NFM{KM7:TR?= NHLFV3FUSU6JRWK=
SW1417 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyyeItKSzVyPUO4MlA2PTJizszN MXXTRW5ITVJ?
EFO-21 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPsTWM2OD1|OD65N|Q6KM7:TR?= NH7oOGlUSU6JRWK=
MG-63 NH36cGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPTd|JGUUN3ME2zPU4{PDJ2IN88US=> MU\TRW5ITVJ?
LC-2-ad NYfpTJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnYUmFKSzVyPUO5MlU2OTJizszN MkLaV2FPT0WU
NOMO-1 NGrteXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PCeWlEPTB;M{muPFI4PCEQvF2= MlrKV2FPT0WU
COLO-741 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT0TWM2OD12MD6xN|A1KM7:TR?= NEDUR5VUSU6JRWK=
BxPC-3 NY\qNHA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7vNVVKSzVyPUSwMlU3QDZizszN NFzkOnFUSU6JRWK=
HSC-2 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[1TWM2OD12MD65NVE{KM7:TR?= M4\FUnNCVkeHUh?=
UMC-11 NE\YelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HubWlEPTB;NEGuNlY{KM7:TR?= NITKRoVUSU6JRWK=
HCC1937 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTiVIRWUUN3ME20Nk44QDR|IN88US=> M3fTdXNCVkeHUh?=
Calu-6 NWO3TGlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILBbldKSzVyPUSzMlI{QDJizszN M13TT3NCVkeHUh?=
NCI-H1573 NHHLbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn1OnBOUUN3ME20N{4{PDd5IN88US=> NVnFXIc3W0GQR1XS
SK-N-AS NUHzRZNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfleFFIUUN3ME20N{43ODF7IN88US=> NIHUbpBUSU6JRWK=
PSN1 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7QOm9KSzVyPUS1MlI2PDhizszN M3TCZ3NCVkeHUh?=
TE-11 NFfXeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDmTWM2OD12NT60PFQzKM7:TR?= M3myR3NCVkeHUh?=
NCI-H1155 NXyxZVA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXCO5JYUUN3ME20OU45QTZ5IN88US=> NFS5VW5USU6JRWK=
KM12 NVTv[XpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTR3LkmwO|Yh|ryP NXPGe5l[W0GQR1XS
RO82-W-1 Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\McYt[UUN3ME20Ok46QDJ{IN88US=> M3HUV3NCVkeHUh?=
SW1573 M1eyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR5LkO3N|Yh|ryP MXTTRW5ITVJ?
CAKI-1 NFizTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7pTWM2OD12OD6yPFQ2KM7:TR?= NFrOVZFUSU6JRWK=
U-118-MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTR6LkO3NFIh|ryP M{nQVHNCVkeHUh?=
KYSE-520 NE\ESmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPUbIJKSzVyPUS4MlQxOTZizszN MoDMV2FPT0WU
HT55 M{C1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR7LkG0O|Qh|ryP MkXpV2FPT0WU
ChaGo-K-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS5c2RKSzVyPUS5MlQ4QTNizszN M4PwRXNCVkeHUh?=
IA-LM MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3qTWM2OD13ND62N|IzKM7:TR?= MUTTRW5ITVJ?
UACC-62 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXNTWM2OD13NT6xNFQ3KM7:TR?= NFjwVmlUSU6JRWK=
MKN7 M2\ZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\jTWM2OD13Nj6wNlg2KM7:TR?= NYnmfpBZW0GQR1XS
HPAF-II NVHFZpFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTV4LkSwO|Mh|ryP NUX4ephbW0GQR1XS
NTERA-S-cl-D1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nqPWlEPTB;NUeuO|c5KM7:TR?= NW\TUpVwW0GQR1XS
FTC-133 NUnuNJZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjyTWM2OD13OD6wPVY6KM7:TR?= MYTTRW5ITVJ?
MHH-ES-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDRSndKSzVyPUW4MlQ5OTRizszN NGC2WXRUSU6JRWK=
JVM-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiyVoNKSzVyPUW4Mlk2ODZizszN MmrQV2FPT0WU
TCCSUP MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnRUHdKSzVyPUW5MlUzPzlizszN Ml7hV2FPT0WU
COLO-824 M13n[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSyVXJKSzVyPU[wMlA4OTlizszN NEPGVW5USU6JRWK=
647-V MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTCTopGUUN3ME22NE4yOzR5IN88US=> MUHTRW5ITVJ?
HD-MY-Z NVzoRWM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:zTWM2OD14MD61Nlk1KM7:TR?= NWHicIlkW0GQR1XS
LS-411N Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHZTWM2OD14MT6zPVA{KM7:TR?= MWDTRW5ITVJ?
NCI-H596 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\uTmlEPTB;NkKuO|Q6PiEQvF2= NIHSVHBUSU6JRWK=
C-33-A NWHCb2M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTZ2LkC5OVch|ryP M1naV3NCVkeHUh?=
BHY Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZ2LkGyOFUh|ryP NIfv[GlUSU6JRWK=
KGN NW\lUmdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf1fldKSzVyPU[0MlU2OTRizszN M4D3WXNCVkeHUh?=
NCI-H1092 NWT0eWxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HTdWlEPTB;NkWuNFA6PSEQvF2= MknXV2FPT0WU
MZ1-PC M4roT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTZ3LkW2OFkh|ryP MWPTRW5ITVJ?
LB831-BLC M17VdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LZcWlEPTB;NkWuPFQ5OSEQvF2= NWrER4hDW0GQR1XS
SW620 NY\qUlBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTZ4LkKwN|kh|ryP M3niTnNCVkeHUh?=
HuO-3N1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HSOWlEPTB;NkiuN|I{QCEQvF2= NETyPVFUSU6JRWK=
SK-HEP-1 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LnVmlEPTB;NkmuPVQ5PiEQvF2= M17qZ3NCVkeHUh?=
LCLC-103H MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTdyLk[3NFUh|ryP MXnTRW5ITVJ?
KYSE-70 NXPvT4l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[5TWM2OD15MD63PFM2KM7:TR?= MkTLV2FPT0WU
Mewo MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL3UXlXUUN3ME23NU42ODVizszN MmDiV2FPT0WU
COLO-668 M{nhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTdzLki0OVEh|ryP NUXadIxsW0GQR1XS
NCI-H522 M1O5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjQVIxuUUN3ME23Nk4{PDF|IN88US=> MX\TRW5ITVJ?
NCI-H1437 NGjkXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml31TWM2OD15ND60NFQ5KM7:TR?= M3iyWnNCVkeHUh?=
U-266 M3y2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;G[WlEPTB;N{WuOFUyPiEQvF2= M{jnTXNCVkeHUh?=
MC116 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPu[WdKSzVyPUe1MlU4ODhizszN M2XheHNCVkeHUh?=
PANC-10-05 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv0W49PUUN3ME23O{41OjR|IN88US=> M2PsXHNCVkeHUh?=
KYSE-180 M1e5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj5Not7UUN3ME23O{42PDV2IN88US=> M2TsenNCVkeHUh?=
JAR NXPrXnFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnMTVlFUUN3ME23PU4xPTR4IN88US=> NH\MSmZUSU6JRWK=
CAL-62 M1XUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRThyLkC5OUDPxE1? Ml;YV2FPT0WU
A3-KAW M{S3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRThyLkKxOVQh|ryP NF\GPXNUSU6JRWK=
PANC-08-13 M2LPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrLUY9YUUN3ME24NU4yPzZ6IN88US=> M2njVHNCVkeHUh?=
HSC-3 NXjzN4hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\ZPZpKSzVyPUizMlMxPzFizszN M3HVenNCVkeHUh?=
HTC-C3 M1nCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnkTWM2OD16Mz60O|AzKM7:TR?= NV7IVJd4W0GQR1XS
KY821 M2TIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfnU2xKSzVyPUi0MlA5QTJizszN NEnleJFUSU6JRWK=
DoTc2-4510 M3PNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rOe2lEPTB;OESuNlE5PSEQvF2= NFTk[IZUSU6JRWK=
NCI-H1581 NI\hVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SyVWlEPTB;OEWuOFY1OSEQvF2= MmfjV2FPT0WU
KARPAS-299 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT6UIJKSzVyPUi2MlE6PzdizszN MYPTRW5ITVJ?
IST-MEL1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7lTWM2OD16Nj64PFczKM7:TR?= M1q0V3NCVkeHUh?=
KP-N-YS MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW3U5RKSzVyPUi5MlkxOjhizszN NYTBZ5hvW0GQR1XS
KYSE-410 M1XkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHjTWM2OD17MT60NFQzKM7:TR?= M4G5VHNCVkeHUh?=
TE-10 NFnk[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLodHhXUUN3ME25NU42PjFzIN88US=> MmjLV2FPT0WU
SK-MEL-1 NH[1UplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT5TWM2OD17Mj65NVA3KM7:TR?= MoTYV2FPT0WU
COLO-792 NFTncmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTl3LkK1OlQh|ryP MYrTRW5ITVJ?
SCH M3fsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3vT5ZKUUN3ME25Ok4{QDd5IN88US=> M3zoRnNCVkeHUh?=
NCI-H1792 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTl4Lki5PVIh|ryP MXrTRW5ITVJ?
NCI-H2029 NVTGXFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHVTWM2OD17Nj65OVY3KM7:TR?= NIj3TpdUSU6JRWK=
SW684 M1TtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTxTWM2OD17OD62OlU1KM7:TR?= NUO1VIxWW0GQR1XS
NCI-H209 NEi4eXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC4SYVKSzVyPUGwNE4yOjFizszN M3TwfHNCVkeHUh?=
HLE NFHnPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLITWM2OD1zMEWuNlgzKM7:TR?= M1\ye3NCVkeHUh?=
GOTO M4nrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHtempKSzVyPUGwO{44PzdizszN NED6cmdUSU6JRWK=
NCI-H1793 M2DCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u1ZmlEPTB;MUC5MlI5KM7:TR?= NWTVbnNnW0GQR1XS
D-392MG M3uxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;1TWM2OD1zMUeuN|k5KM7:TR?= M4\WNXNCVkeHUh?=
SW1990 NIfNNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPifm1KSzVyPUGyNE46PTFizszN M3TUW3NCVkeHUh?=
ML-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF{MT62O|Yh|ryP M1LtXHNCVkeHUh?=
NCI-H2452 NIjuZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PlVWlEPTB;MUKyMlIyKM7:TR?= M4nN[HNCVkeHUh?=
SK-MEL-30 NXXBTmtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nYZWlEPTB;MUKzMlI1PCEQvF2= NF;KdGlUSU6JRWK=
SN12C M2nudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrqc4xKSzVyPUGyOE4yPzZizszN NFriV2RUSU6JRWK=
NCI-H1770 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPtW2NPUUN3ME2xNlUvPTF2IN88US=> NHjkb4NUSU6JRWK=
SF268 M3XQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF{Nj6xOVgh|ryP M3nHbXNCVkeHUh?=
BALL-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HBfWlEPTB;MUK2MlI{KM7:TR?= MlnHV2FPT0WU
COLO-679 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzwZ3NKSzVyPUGyOk44PTNizszN MmDZV2FPT0WU
A2780 NYD3RZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe5R5F4UUN3ME2xNlgvQTh6IN88US=> NV;3R4ZOW0GQR1XS
NCI-H1651 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF|MT6yOFMh|ryP NYrlTGp2W0GQR1XS
NCI-H2087 NHfXVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXme2JKSzVyPUGzNU41QDNizszN NVvEPXhSW0GQR1XS
U-87-MG NFPLNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHNcVRKSzVyPUGzN{43ODRizszN NF;ye4JUSU6JRWK=
LB2518-MEL NUG3NIt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXNTWM2OD1zM{WuPVk{KM7:TR?= MUXTRW5ITVJ?
HCT-116 NHezNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G3[WlEPTB;MUO3MlIyPyEQvF2= MlzXV2FPT0WU
Ca9-22 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TxPGlEPTB;MUO5Mlg{OyEQvF2= NVLNfoNxW0GQR1XS
COR-L88 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq4b2pnUUN3ME2xOFIvOTRizszN NInQdFhUSU6JRWK=
CP50-MEL-B NXnpUYFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF2ND61NFEh|ryP Mn2wV2FPT0WU
OVCAR-8 Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrpVlY4UUN3ME2xOFUvPjN4IN88US=> MonRV2FPT0WU
SK-MEL-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDGV|N3UUN3ME2xOFcvQDd6IN88US=> NUHqSW86W0GQR1XS
GT3TKB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH6yTGlKSzVyPUG0PU46OjhizszN MnvRV2FPT0WU
KYSE-450 NEDTN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj6TWM2OD1zNUGuOVM6KM7:TR?= NGDiWYZUSU6JRWK=
CAPAN-1 NX3iVXVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;V[WlEPTB;MUWzMlA3PCEQvF2= NX7qT414W0GQR1XS
BEN MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF3Mz65Nlgh|ryP NGrYTlVUSU6JRWK=
NCI-H1304 NXj4T2RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIeyTo1KSzVyPUG1OE43QTRizszN NXnhbVZqW0GQR1XS
KU812 NELsO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn0NoJZUUN3ME2xOVgvPjd2IN88US=> MkjaV2FPT0WU
Capan-2 M4\OfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDi[ldKSzVyPUG2NE42PTNizszN MV\TRW5ITVJ?
A673 NFHmXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF4MT63NFUh|ryP NIrnWmlUSU6JRWK=
SAS MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zRbGlEPTB;MU[yMlY4QCEQvF2= NHnofVlUSU6JRWK=
NY MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i2S2lEPTB;MU[1MlMyPCEQvF2= NITGNpBUSU6JRWK=
HCE-4 M2[1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPLWVRyUUN3ME2xOlYvQDR3IN88US=> MVrTRW5ITVJ?
MDA-MB-231 M1zUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7VTWM2OD1zN{euOVA{KM7:TR?= MkDYV2FPT0WU
no-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF5OD6xN|Qh|ryP MV;TRW5ITVJ?
MZ7-mel M4HlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWxXGRKSzVyPUG3PE41PjdizszN MUjTRW5ITVJ?
NCI-H82 M3rNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW5TWM2OD1zOECuNVY2KM7:TR?= NXL3fpVqW0GQR1XS
CAL-72 NIrUbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT2VpFKSzVyPUG4OU4xPTRizszN MYfTRW5ITVJ?
NCI-SNU-5 NHnZOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP1NXlsUUN3ME2xPFYvQDRizszN Mkj3V2FPT0WU
OVCAR-4 M{i3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n2cmlEPTB;MUi4MlM{OyEQvF2= NWWwVpVwW0GQR1XS
SCC-9 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX35SplxUUN3ME2xPVEh|ryP MXvTRW5ITVJ?
KYSE-150 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\vTWM2OD1zOUGuPFg5KM7:TR?= NVzpVll7W0GQR1XS
HT-29 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJyMT6yNVIh|ryP NV70eYg3W0GQR1XS
COLO-678 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XQXGlEPTB;MkCxMlQ2KM7:TR?= NEHjXHpUSU6JRWK=
NCI-H650 NXXWSXI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fqW2lEPTB;MkCyMlExOyEQvF2= NIXIfFNUSU6JRWK=
HuCCT1 M{PyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfMOVJ{UUN3ME2yNFQvOjB6IN88US=> MmX5V2FPT0WU
SW1116 NYTUfZp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDMbG9KSzVyPUKwO{4xPzdizszN NV;1WWdlW0GQR1XS
DBTRG-05MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXkTWM2OD1{MEeuPVA6KM7:TR?= MnvGV2FPT0WU
SW982 NUWxZZdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XEU2lEPTB;MkC3Mlk1QCEQvF2= Mm\SV2FPT0WU
RCM-1 NITUfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWewTXM4UUN3ME2yNVQvPzZ{IN88US=> NYDKOZhuW0GQR1XS
COLO-320-HSR M{W3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWezVJNPUUN3ME2yNVYvOTJ3IN88US=> NUDXWGpFW0GQR1XS
KNS-42 NI\HOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJzNj61O|Qh|ryP M2fPfnNCVkeHUh?=
C2BBe1 NFjveGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHy1b21KSzVyPUKzNU46ODVizszN MnnxV2FPT0WU
CCRF-CEM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPPTWM2OD1{NEOuO|k2KM7:TR?= MUHTRW5ITVJ?
SH-4 NHj2XoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuyS5VKSzVyPUK0Ok4xQSEQvF2= NVrsUmNDW0GQR1XS
LS-1034 NYjkNFV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\vdGlEPTB;MkS2MlI3PiEQvF2= Mly1V2FPT0WU
NCI-H2347 M2roVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHPTWM2OD1{NEeuO|E{KM7:TR?= NFrF[WFUSU6JRWK=
RPMI-8866 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TaWWlEPTB;MkS5MlI4KM7:TR?= NE[5dWJUSU6JRWK=
GAK NEmyUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELndIdKSzVyPUK1N{4xODJizszN NFvue5lUSU6JRWK=
NB6 NVnYPZJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PyXmlEPTB;MkewMlEh|ryP NYG5TFVOW0GQR1XS
COLO-680N NX;CTVMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXHVIZKSzVyPUK3Nk42OjdizszN NHn5eoVUSU6JRWK=
RERF-LC-MS NVvKXWp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ5Nj6wNFch|ryP MnnkV2FPT0WU
TGBC11TKB NX\3S41CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli3TWM2OD1{N{iuNVc5KM7:TR?= NHH1[VBUSU6JRWK=
C8166 MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Fd|hKSzVyPUK3PE42ODZizszN M33CdXNCVkeHUh?=
HDLM-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLJeFJPUUN3ME2yPVQvPDB7IN88US=> MmXzV2FPT0WU
IGR-1 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HSe2lEPTB;Mkm1MlY2QSEQvF2= MoD1V2FPT0WU
FADU NV3qfmllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnBe5FOUUN3ME2yPVcvPTFizszN M3nXN3NCVkeHUh?=
L-428 NHzjUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS4TWM2OD1{OUeuOlE3KM7:TR?= NGnxOVNUSU6JRWK=
LU-65 M4\rVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XNOWlEPTB;M{C0MlMzKM7:TR?= MUPTRW5ITVJ?
HEL M1\uSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\OTWM2OD1|MEmuPVg{KM7:TR?= NVq1Z5gxW0GQR1XS
NCI-H810 NF23cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzwXGtUUUN3ME2zNVAvPTdizszN NUXIU3l6W0GQR1XS
C3A MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\tTWM2OD1|MUGuPFAzKM7:TR?= M{HER3NCVkeHUh?=
NCI-H630 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTN|Mj6yPVQh|ryP M1HFbnNCVkeHUh?=
KP-N-YN M3TURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN2MT6xNlMh|ryP M4K3V3NCVkeHUh?=
MOLT-13 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH6e|hKSzVyPUO0Nk4{OjZizszN NWrnPIgxW0GQR1XS
NCI-H1993 NXfXfmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P0NmlEPTB;M{SyMlM3PSEQvF2= MnzPV2FPT0WU
BE-13 M{TQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;DXZpKSzVyPUO0OE4yPjdizszN NXnSTpE{W0GQR1XS
IST-SL1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITteIhKSzVyPUO0O{41ODFizszN NIfhN2xUSU6JRWK=
TE-9 NXzlbow6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq5cpdKSzVyPUO2N{42QDlizszN MYnTRW5ITVJ?
LU-135 NH7yd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrXZ4dKSzVyPUO2O{4xOzVizszN NHm1eoRUSU6JRWK=
T84 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDGbpRmUUN3ME2zO|QvPzF{IN88US=> M3e4TnNCVkeHUh?=
K-562 NVvMR5h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrWVWFKSzVyPUO4N{4{PiEQvF2= MVPTRW5ITVJ?
SBC-5 M{jkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTIRnpKSzVyPUO4Ok46QDVizszN MkjzV2FPT0WU
NB17 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPUTWM2OD1|OUKuOVk3KM7:TR?= MnfVV2FPT0WU
NCI-H2052 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS3Z5hKSzVyPUO5PE41PzJizszN NF[1TGFUSU6JRWK=
HCC38 M3e1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTRyMT61PVMh|ryP NET5eVlUSU6JRWK=
NCI-H69 M2D6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTR2MT6wPFMh|ryP M3;lcHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]

+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]

+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
15% Captisol
For best results, use promptly after mixing.
17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID